These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 34893922)
1. Comparison of Predictions by BCS, rDCS and Machine Learning for the Effect of Food on Oral Drug Absorption Based on Features Calculated In silico. Hoshino Y; Yoshioka H; Hisaka A AAPS J; 2021 Dec; 24(1):10. PubMed ID: 34893922 [TBL] [Abstract][Full Text] [Related]
5. Comparing multilabel classification methods for provisional biopharmaceutics class prediction. Newby D; Freitas AA; Ghafourian T Mol Pharm; 2015 Jan; 12(1):87-102. PubMed ID: 25397721 [TBL] [Abstract][Full Text] [Related]
6. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626 [TBL] [Abstract][Full Text] [Related]
7. Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data. Heimbach T; Xia B; Lin TH; He H AAPS J; 2013 Jan; 15(1):143-58. PubMed ID: 23139017 [TBL] [Abstract][Full Text] [Related]
8. Is the full potential of the biopharmaceutics classification system reached? Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971 [TBL] [Abstract][Full Text] [Related]
9. Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number. Pham-The H; Garrigues T; Bermejo M; González-Álvarez I; Monteagudo MC; Cabrera-Pérez MÁ Mol Pharm; 2013 Jun; 10(6):2445-61. PubMed ID: 23675957 [TBL] [Abstract][Full Text] [Related]
10. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482 [TBL] [Abstract][Full Text] [Related]
11. The developability classification system: application of biopharmaceutics concepts to formulation development. Butler JM; Dressman JB J Pharm Sci; 2010 Dec; 99(12):4940-54. PubMed ID: 20821390 [TBL] [Abstract][Full Text] [Related]
12. A modified physiological BCS for prediction of intestinal absorption in drug discovery. Zaki NM; Artursson P; Bergström CA Mol Pharm; 2010 Oct; 7(5):1478-87. PubMed ID: 20734997 [TBL] [Abstract][Full Text] [Related]
13. Simulation-based comparison of Biopharmaceutics Classification System and drug structure. Chen T; Wu T; Li N; Jiang Y; Yin H; Wu M Pharmazie; 2020 Apr; 75(4):124-130. PubMed ID: 32295687 [No Abstract] [Full Text] [Related]
14. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines. Charalabidis A; Sfouni M; Bergström C; Macheras P Int J Pharm; 2019 Jul; 566():264-281. PubMed ID: 31108154 [TBL] [Abstract][Full Text] [Related]
15. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464 [TBL] [Abstract][Full Text] [Related]
16. Analysis of five active ingredients of Er-Zhi-Wan, a traditional Chinese medicine water-honeyed pill, using the biopharmaceutics classification system. Cao X; Li H; Wang M; Ren X; Deng Y Biomed Chromatogr; 2020 Feb; 34(2):e4757. PubMed ID: 31755125 [TBL] [Abstract][Full Text] [Related]
17. Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery. Larregieu CA; Benet LZ Mol Pharm; 2014 Apr; 11(4):1335-44. PubMed ID: 24628254 [TBL] [Abstract][Full Text] [Related]
18. Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models. Hansmann S; Darwich A; Margolskee A; Aarons L; Dressman J J Pharm Pharmacol; 2016 Dec; 68(12):1501-1515. PubMed ID: 27781273 [TBL] [Abstract][Full Text] [Related]
19. Biorelevant Two-Stage In Vitro Testing for rDCS Classification and in PBPK Modeling-Case Example Ritonavir. Fiolka T; Van Den Abeele J; Augustijns P; Arora S; Dressman J J Pharm Sci; 2020 Aug; 109(8):2512-2526. PubMed ID: 32387425 [TBL] [Abstract][Full Text] [Related]
20. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Wu CY; Benet LZ Pharm Res; 2005 Jan; 22(1):11-23. PubMed ID: 15771225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]